TSL Thinksmart Limited

RNS Number:2487P
Tissue Science Laboratories PLC
25 July 2005



                                                                    25 July 2005
                        Tissue Science Laboratories plc
                            ('TSL' or 'the Company')

                    TSL Acquires New Manufacturing Facility

Tissue Science Laboratories plc (LSE: TSL), the medical devices company
specialising in human tissue replacement and repair products derived from
porcine dermis, is pleased to announce the acquisition of a new industrial unit
near Leeds for
c.#1.7 million.

The new freehold is approximately 30,000 square feet and will provide new
offices, laboratories, warehousing and manufacturing space. It is a short
distance from the current manufacturing facility in Swillington and it will
provide space for the Company's product development programmes. The facility
will be phased in over a three year period as part of the planned development of
the business.

The acquisition has been financed with a 20 year commercial mortgage provided by
Barclay's Bank.

Martin Hunt, Chief Executive of TSL, said:
"With the planned acceleration of our product development, the securing of this
new space has been essential to our continued growth. We see this as another
milestone in the Company's development and we are excited about the potential
opportunities this will enable us to exploit."

                                     -Ends-

For further information, please contact:

TSL plc                                              Tel: 01252 369603
Martin Hunt, Chief Executive

Hogarth Partnership Limited                          Tel: 020 7357 9477
Melanie Toyne-Sewell / Kate Catchpole



Notes to Editors

Background on TSL

Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product, derived from porcine dermis, called Permacol(R). TSL
has successfully launched different formulations of the product and built a
development pipeline that addresses the large and fast growing surgical implant
market.  The Company floated in November 2001 and is listed on the AIM (LSE:
TSL).

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications, including urology/gynaecology, complex and recurrent
hernia repair, shoulder rotator cuff repair and head and face repair and
reconstruction. The Company has signed distribution agreements with CR Bard Inc
(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) and
Porex Surgical Inc (head & face-US and Canada). Further variations of the sheet
and injectable forms of Permacol(R) are being developed.

Background on Permacol(R)

Permacol(R) was developed at Dundee University over a 20 year time period and
has been patented worldwide. The key to the Permacol(R) concept lies in its
collagen Technology which uses non-reconstituted porcine dermal collagen, very
similar in structure to human tissue. Non-collagenous material, except elastin,
is removed by the TSL manufacturing process. The remaining collagen, which
retains its original 3-D structural architecture, is stabilised by a patented
cross-linking process. The result is a non-reconstituted, non-allergenic,
collagen implant which is resistant to biodegradation attack, is recognised and
accepted by the body, and is able to provide a long-term support for the
in-growth of new tissue and its associated blood supply.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBGGDRRBDGGUU

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024